

# Regence

Medicare Advantage Policy Manual

Policy ID: M-RAD37

## Ultrasonographic Measurement of Carotid Artery Intima-Media Thickness as an Assessment of Atherosclerosis

Published: 03/01/2024

Next Review: 12/2024

Last Review: 01/2024

Medicare Link(s) Revised: 03/01/2024

### IMPORTANT REMINDER

*The Medicare Advantage Medical Policy manual is not intended to override the member Evidence of Coverage (EOC), which defines the insured's benefits, nor is it intended to dictate how providers are to practice medicine. Physicians and other health care providers are expected to exercise their medical judgment in providing the most appropriate care for the individual member.*

*The Medicare Advantage Medical Policies are designed to provide guidance regarding the decision-making process for the coverage or non-coverage of services or procedures in accordance with the member EOC and the Centers of Medicare and Medicaid Services (CMS) policies, when available. In the event of a conflict, applicable CMS policy or EOC language will take precedence over the Medicare Advantage Medical Policy. In the absence of CMS guidance for a requested service or procedure, the health plan may apply their Medical Policy Manual or MCG™ criteria, both of which are developed with an objective, evidence-based process using scientific evidence, current generally accepted standards of medical practice, and authoritative clinical practice guidelines.*

*Medicare and EOCs exclude from coverage, among other things, services or procedures considered to be investigational, cosmetic, or not medically necessary, and in some cases, providers may bill members for these non-covered services or procedures. Providers are encouraged to inform members in advance when they may be financially responsible for the cost of non-covered or excluded services.*

## DESCRIPTION

Ultrasonographic measurement of carotid intima-medial (also called intimal-medial or intima-media) thickness (CIMT) is used as a marker of subclinical atherosclerosis. Ultrasonographic measurement of CIMT has been investigated as a screening tool for cardiovascular risk, as a proxy for progression of atherosclerosis, and is proposed for use in identifying and monitoring subclinical coronary heart disease (CHD).

## MEDICARE ADVANTAGE POLICY CRITERIA

<b>CMS Coverage Manuals*</b>	None
<b>National Coverage Determinations (NCDs)*</b>	None

---

**Noridian Healthcare Solutions (Noridian) Local Coverage Determinations (LCDs) and Articles\***      None

---

**Medical Policy Manual**

*Medicare coverage guidance is not available for the ultrasonographic measurement of the carotid artery intima-media thickness. Therefore, the health plan's medical policy is applicable.*

Ultrasonographic Measurement of Carotid Artery Intima-Media Thickness as an Assessment of Atherosclerosis, Radiology, [Policy No. 37](#) (see "NOTE" below)

---

**NOTE:** If a procedure or device lacks scientific evidence regarding safety and efficacy because it is investigational or experimental, the service is noncovered as not reasonable and necessary to treat illness or injury. ([Medicare IOM Pub. No. 100-04, Ch. 23, §30.A](#)). According to Title XVIII of the Social Security Act, §1862(a)(1)(A), only medically reasonable and necessary services are covered by Medicare. In the absence of a NCD, LCD, or other coverage guideline, CMS guidelines allow a Medicare Advantage Organization (MAO) to make coverage determinations, applying an **objective, evidence-based process, based on authoritative evidence**. ([Medicare IOM Pub. No. 100-16, Ch. 4, §90.5](#)). The Medicare Advantage Medical Policy - Medicine Policy No. M-149 - provides further details regarding the plan's evidence-assessment process (see Cross References).

---

## POLICY GUIDELINES

### REGULATORY STATUS

In February 2003, SonoCalc® (SonoMetric Health, LLC) was cleared for marketing by the FDA through the 510(k) process. The FDA determined that this software was substantially equivalent to image display products from existing ultrasound systems. Subsequently, several other devices have been approved through the 510(k) process.

Note, the fact a new service or procedure has been issued a CPT/HCPCS code or is FDA approved for a specific indication does not, in itself, make the procedure medically reasonable and necessary. The FDA determines safety and effectiveness of a device or drug, but does not establish medical necessity. While Medicare may adopt FDA determinations regarding safety and effectiveness, Medicare or Medicare contractors evaluate whether or not the drug or device is reasonable and necessary for the Medicare population under §1862(a)(1)(A).

## CROSS REFERENCES

[Investigational \(Experimental\) Services, New and Emerging Medical Technologies and Procedures, and Other Non-Covered Services](#), Medicine, Policy No. M-149

## REFERENCES

---

None

## CODING

**NOTE:** CPT 93880 (duplex scan of extracranial arteries; complete bilateral study) should not be used to identify carotid intima-media thickness studies.

Codes	Number	Description
CPT	93895	Quantitative carotid intima media thickness and carotid atheroma evaluation, bilateral
HCPCS	None	

**\*IMPORTANT NOTE:** Medicare Advantage medical policies use the most current Medicare references available at the time the policy was developed. Links to Medicare references will take viewers to external websites outside of the health plan's web control as these sites are not maintained by the health plan.